Fecobionics in Biofeedback Therapy in Dyssynergia Patients

Sponsor
The California Medical Innovations Institute, Inc. (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05807321
Collaborator
Scripps Clinic (Other)
24
1
1
22.5
1.1

Study Details

Study Description

Brief Summary

Constipation affects 12-19% of Americans. Pelvic floor dyssynergia is considered to play an important role in constipation but the underlying mechanisms are not well understood in individual patients. The investigators have developed a novel device named Fecobionics that provide detailed mapping of physiological parameters during defecation. The aim of the study is to use Fecobionics to assess anorectal function in dyssynergia patients and monitor and predict the outcome of the biofeedback therapy.

Condition or Disease Intervention/Treatment Phase
  • Device: Fecobionics
N/A

Detailed Description

This study aims to monitor and predict biofeedback therapy based on mechanism-based and highly integrated data using a new medical device. This study is specifically for patients with dyssynergia before, during, and after biofeedback therapy. The balloon-like Fecobionics device (10 cm long and 1 cm in diameter) will be inserted into the participant's rectum and will record data before and during the expulsion of the device. The participant will be asked to do different motions like cough, squeeze, or push during the procedure. The novel data obtained in this study may help the investigators to identify the patients who will benefit or not benefit from biofeedback therapy before the therapy is done. This will determine the effectiveness of treatments for anorectal disorders.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
24 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Fecobionics to Monitor and Predict Biofeedback Therapy in Dyssynergia Patients
Anticipated Study Start Date :
May 15, 2023
Anticipated Primary Completion Date :
Jan 1, 2025
Anticipated Study Completion Date :
Mar 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Fecobionics

Device: Fecobionics
Fecobionics is a novel device to be inserted through the anal canal into rectum for studying defecation. Anorectal manometry and balloon expulsion test may be used as reference. Anorectal manometry and balloon expulsive test are standard methods for anorectal functional measurement.
Other Names:
  • Anorectal manometry
  • Balloon expulsive test
  • Outcome Measures

    Primary Outcome Measures

    1. Expulsion Duration [1.5 year]

      The time it takes to defecate Fecobionics

    2. Pressure Difference between front and rear ends of Fecobionics [1.5 year]

      A measure of anal sphincter pressure, the driving rectal pressure, and the difference between these two pressures. This is the key to the determination of defecation phases.

    Secondary Outcome Measures

    1. Anorectal angle [1.5 year]

      Anorectal angle is an important parameter for defecation

    2. Mechanical Tension of Fecobionics [1.5 year]

      To reflect anorectal function, the mechanical tension will be computed. The tension is equal to anorectal radius multiply pressure.

    3. Expulsion Velocity [1.5 year]

      Measured from the time difference between multiple sensor data

    4. Cross-sectional area [1.5 year]

      Computed by diameter

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    21 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Subject must provide written informed consent.

    2. Age between 21-75 years.

    3. Subjects must fulfill the criteria for obstructed defecation/dyssynergia and enter the BFT at UCSD or Scripps.

    Exclusion Criteria:
    1. Female who is pregnant or lactating.

    2. Prior abdominal or anorectal surgery or bowel resection.

    3. Diagnosis of fecal incontinence, any anorectal symptoms and drug use that affect anorectal function.

    4. Confirmed or suspected COVID-19 infection.

    5. Severe cardiovascular disease.

    6. Subjects not willing to consent and undergo the specified tests in this study.

    7. Other exclusions, that in the opinion of the investigator, the volunteer is not a suitable subject for the study.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 California Medical Innovations Institute San Diego California United States 92121

    Sponsors and Collaborators

    • The California Medical Innovations Institute, Inc.
    • Scripps Clinic

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Hans Gregersen, PhD, CEO, The California Medical Innovations Institute, Inc.
    ClinicalTrials.gov Identifier:
    NCT05807321
    Other Study ID Numbers:
    • CALM-CLIN-2023 BFT
    First Posted:
    Apr 11, 2023
    Last Update Posted:
    Apr 14, 2023
    Last Verified:
    Apr 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Hans Gregersen, PhD, CEO, The California Medical Innovations Institute, Inc.
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 14, 2023